The role of interleukin‑7 serum level as biological marker in breast cancer: a cross‑sectional, observational, and analytical study.
Biomarker
Breast cancer
Croatia
Interleukin-7
Interleukins
Kosovo
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
06 Jul 2022
06 Jul 2022
Historique:
received:
16
12
2021
accepted:
28
04
2022
entrez:
6
7
2022
pubmed:
7
7
2022
medline:
9
7
2022
Statut:
epublish
Résumé
The important role that the immune system plays in malignant diseases is well known. The action of interleukin-7 (IL-7) as a cytokine has been observed in many cellular processes, both in normal cells of the immune system and in some cancer cells. The aim of this study has been to explore whether there is any elevation of interleukin-7 serum levels in early invasive breast cancer (EIBC) patients in comparison with healthy controls. In addition, the correlation between the IL-7 serum level and the histopathological characteristics of the tumor has been evaluated. This cross-sectional, observational, and analytical study included 213 consecutive patients with EIBC (113 from Croatia and 100 from Kosovo) and 62 healthy participants as the control group (30 from Croatia and 32 from Kosovo). Blood samples have been taken from patients confirmed with breast cancer (BC) by biopsy, prior to surgical intervention and other oncological treatments, as well as from healthy participants. A serum IL-7 level has been measured, using the "Sandwich" ELISA Immunoenzyme test. In addition, after the surgical intervention, histopathological specimen examinations and immunohistochemistry have been performed and analyzed. The differences in the distribution of the numerical variables have been analyzed with the Mann-Whitney U test and Kruskal-Wallis ANOVA test. Correlations have been tested with Pearson coefficients. A P-value < 0.05 has been accepted as statistically significant. The serum level of IL-7 in EIBC patients was significantly higher than in control cases (P 0.001). Patients with invasive lobular carcinoma (ILC) seem to have a lower IL-7 serum level compared to other histological subtypes, and the difference has been significant (P = 0.043). There has been no correlation between IL-7 serum level and histopathological characteristics of the tumor, with neither age nor menopausal status of the patients. Noting the significant increase in the IL-7 serum level in the EIBC patients as compared to the healthy control group, the use of IL-7 as a potential diagnostic indicator for BC, as well as in the follow-up of the patients after treatment, can be assumed. The lack of correlation with tumor size, lymph node metastasis, and all other histopathological characteristics of the tumor questions its use as a prognostic indicator.
Sections du résumé
BACKGROUND
BACKGROUND
The important role that the immune system plays in malignant diseases is well known. The action of interleukin-7 (IL-7) as a cytokine has been observed in many cellular processes, both in normal cells of the immune system and in some cancer cells. The aim of this study has been to explore whether there is any elevation of interleukin-7 serum levels in early invasive breast cancer (EIBC) patients in comparison with healthy controls. In addition, the correlation between the IL-7 serum level and the histopathological characteristics of the tumor has been evaluated.
METHODS
METHODS
This cross-sectional, observational, and analytical study included 213 consecutive patients with EIBC (113 from Croatia and 100 from Kosovo) and 62 healthy participants as the control group (30 from Croatia and 32 from Kosovo). Blood samples have been taken from patients confirmed with breast cancer (BC) by biopsy, prior to surgical intervention and other oncological treatments, as well as from healthy participants. A serum IL-7 level has been measured, using the "Sandwich" ELISA Immunoenzyme test. In addition, after the surgical intervention, histopathological specimen examinations and immunohistochemistry have been performed and analyzed. The differences in the distribution of the numerical variables have been analyzed with the Mann-Whitney U test and Kruskal-Wallis ANOVA test. Correlations have been tested with Pearson coefficients. A P-value < 0.05 has been accepted as statistically significant.
RESULTS
RESULTS
The serum level of IL-7 in EIBC patients was significantly higher than in control cases (P 0.001). Patients with invasive lobular carcinoma (ILC) seem to have a lower IL-7 serum level compared to other histological subtypes, and the difference has been significant (P = 0.043). There has been no correlation between IL-7 serum level and histopathological characteristics of the tumor, with neither age nor menopausal status of the patients.
CONCLUSIONS
CONCLUSIONS
Noting the significant increase in the IL-7 serum level in the EIBC patients as compared to the healthy control group, the use of IL-7 as a potential diagnostic indicator for BC, as well as in the follow-up of the patients after treatment, can be assumed. The lack of correlation with tumor size, lymph node metastasis, and all other histopathological characteristics of the tumor questions its use as a prognostic indicator.
Identifiants
pubmed: 35794603
doi: 10.1186/s12957-022-02646-7
pii: 10.1186/s12957-022-02646-7
pmc: PMC9258073
doi:
Substances chimiques
Biomarkers, Tumor
0
IL7 protein, human
0
Interleukin-7
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
225Informations de copyright
© 2022. The Author(s).
Références
Oncogene. 2005 Nov 14;24(50):7443-54
pubmed: 16288291
Histochem Cell Biol. 2014 Oct;142(4):401-10
pubmed: 24770666
Clin Cancer Res. 2009 May 1;15(9):2979-87
pubmed: 19366834
Nature. 2012 Feb 08;482(7385):400-4
pubmed: 22318521
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
Anal Bioanal Chem. 2007 Feb;387(3):1027-32
pubmed: 17205273
World J Surg Oncol. 2020 May 30;18(1):117
pubmed: 32473643
Asian Pac J Cancer Prev. 2012;13(10):5307-12
pubmed: 23244154
Clin Cancer Res. 2011 Jun 1;17(11):3660-72
pubmed: 21636553
Cancer Epidemiol Biomarkers Prev. 2017 Sep;26(9):1360-1369
pubmed: 28600297
World J Surg Oncol. 2020 Sep 25;18(1):254
pubmed: 32977823
Int J Mol Sci. 2015 May 06;16(5):10267-80
pubmed: 25955647
PLoS One. 2009 Nov 10;4(11):e7637
pubmed: 19907640
J Clin Oncol. 2016 Jun 1;34(16):1872-81
pubmed: 26926684
Cancer Metastasis Rev. 2011 Mar;30(1):125-40
pubmed: 21249424
World J Surg Oncol. 2021 Jun 25;19(1):188
pubmed: 34172056
Genes Dev. 2018 Oct 1;32(19-20):1267-1284
pubmed: 30275043
Eur J Cancer. 2001 May;37(7):857-61
pubmed: 11313173
Cancer Immunol Immunother. 2012 Feb;61(2):289-293
pubmed: 22237887
Sci Rep. 2018 May 8;8(1):7205
pubmed: 29739984
Immunity. 2008 Dec 19;29(6):848-62
pubmed: 19100699
Blood. 2012 Dec 6;120(24):4675-83
pubmed: 22955921
Mod Pathol. 2019 Sep;32(9):1244-1256
pubmed: 30976105
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nat Immunol. 2007 Nov;8(11):1255-65
pubmed: 17893676
Nat Immunol. 2009 Feb;10(2):149-57
pubmed: 19136960
J Cancer. 2014 Oct 22;5(9):765-73
pubmed: 25368677
Clin Exp Immunol. 2013 Jan;171(1):36-45
pubmed: 23199321
J Exp Med. 1991 Dec 1;174(6):1511-5
pubmed: 1744582
Cytokine. 2007 Jul;39(1):75-83
pubmed: 17768066
Biochem Biophys Res Commun. 2012 Jun 15;422(4):727-31
pubmed: 22618230
Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):513-33
pubmed: 15996891
Breast Cancer Res. 2015 Jan 30;17:12
pubmed: 25849106
World J Surg Oncol. 2011 Feb 06;9:18
pubmed: 21294915
Br J Pharmacol. 2013 Feb;168(3):591-606
pubmed: 23062197
Immunology. 2007 May;121(1):1-14
pubmed: 17386080
CA Cancer J Clin. 2017 Jul 8;67(4):290-303
pubmed: 28294295
Cancer J. 2013 Nov-Dec;19(6):483-9
pubmed: 24270347
J Immunotoxicol. 2010 Mar;7(1):1-7
pubmed: 20017587
Cell Signal. 2002 Apr;14(4):317-25
pubmed: 11858939
Bone Marrow Transplant. 1999 Apr;23(8):783-8
pubmed: 10231140